Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced a collaboration with TARA Mind, working alongside Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The partnership aims to expand mental health awareness within the veteran community by leveraging the networks of TARA Mind and VETS to enhance engagement among veterans.
The announcement aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, as Helus advances its FDA Breakthrough Therapy-designated HLP003 program. Helus is developing HLP003, a proprietary novel serotonergic agonist (NSA), for the adjunctive treatment of major depressive disorder. The company also has HLP004 in Phase 2 for generalized anxiety disorder and an extensive research portfolio of investigational NSAs.
The collaboration is expected to facilitate recruitment for the Phase 3 trial by connecting with veterans who may benefit from the investigational therapy. TARA Mind and VETS provide established channels to reach this population, which faces high rates of depression and other mental health conditions. Helus Pharma aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions through its proprietary NSAs designed to activate serotonin pathways and promote neuroplasticity.
For more information, visit the full press release at https://ibn.fm/o9dCH. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs. The company operates in Canada, the United States, the United Kingdom and Ireland. For more information, visit www.helus.com.
